![Page 1: LAST CLINICAL GUIDELINES DIAGNOSIS AND MANAGEMENT](https://reader031.vdocuments.mx/reader031/viewer/2022012915/61c641d59afa2677e5722175/html5/thumbnails/1.jpg)
COPD LAST CLINICAL GUIDELINES DIAGNOSIS
AND MANAGEMENT
![Page 2: LAST CLINICAL GUIDELINES DIAGNOSIS AND MANAGEMENT](https://reader031.vdocuments.mx/reader031/viewer/2022012915/61c641d59afa2677e5722175/html5/thumbnails/2.jpg)
DR: Tawfik Kamel Al-gherasi
Specialist Internal Medicine
![Page 3: LAST CLINICAL GUIDELINES DIAGNOSIS AND MANAGEMENT](https://reader031.vdocuments.mx/reader031/viewer/2022012915/61c641d59afa2677e5722175/html5/thumbnails/3.jpg)
3
What is COPD??????
►Chronic Obstructive Pulmonary Disease
(COPD):
► is a common, preventable and treatable
disease that is characterized by persistent
respiratory symptoms and airflow limitation that
is due to airway and/or alveolar abnormalities
usually caused by significant exposure to
noxious particles or gases.
![Page 4: LAST CLINICAL GUIDELINES DIAGNOSIS AND MANAGEMENT](https://reader031.vdocuments.mx/reader031/viewer/2022012915/61c641d59afa2677e5722175/html5/thumbnails/4.jpg)
4
What causes COPD??????????
Worldwide, the most commonly encountered risk
factors for COPD are: Indoor air pollution.
Outdoor air pollution.
Occupational exposures.
Genetic factors.
Age and six.
Lung growth and development.
Socioeconomic status.
Asthma and airway hyper-reactivity.
Chronic bronchitis.
Infections.
![Page 5: LAST CLINICAL GUIDELINES DIAGNOSIS AND MANAGEMENT](https://reader031.vdocuments.mx/reader031/viewer/2022012915/61c641d59afa2677e5722175/html5/thumbnails/5.jpg)
5
Etiology, pathobiology & pathology of COPD leading to airflow limitation & clinical manifestations
![Page 6: LAST CLINICAL GUIDELINES DIAGNOSIS AND MANAGEMENT](https://reader031.vdocuments.mx/reader031/viewer/2022012915/61c641d59afa2677e5722175/html5/thumbnails/6.jpg)
6
![Page 7: LAST CLINICAL GUIDELINES DIAGNOSIS AND MANAGEMENT](https://reader031.vdocuments.mx/reader031/viewer/2022012915/61c641d59afa2677e5722175/html5/thumbnails/7.jpg)
7
![Page 8: LAST CLINICAL GUIDELINES DIAGNOSIS AND MANAGEMENT](https://reader031.vdocuments.mx/reader031/viewer/2022012915/61c641d59afa2677e5722175/html5/thumbnails/8.jpg)
8
Diagnosis and Initial Assessment
OVERALL KEY POINTS:
COPD should be considered in any patient who has dyspnea, chronic cough or sputum production, and/or a history of exposure to risk factors for the disease.
Spirometry is required to make the diagnosis; the presence of a post-bronchodilator FEV1/FVC < 0.70 confirms the presence of persistent airflow limitation.
The goals of COPD assessment are to determine the level of airflow limitation, the impact of disease on the patient’s health status, and the risk of future events (such as exacerbations, hospital admissions, or death), in order to guide therapy.
Concomitant chronic diseases occur frequently in COPD patients, including cardiovascular disease, skeletal muscle dysfunction, metabolic syndrome, osteoporosis, depression, anxiety, and lung cancer. These comorbidities should be actively sought and treated appropriately when present as they can influence mortality and hospitalizations independently.
![Page 9: LAST CLINICAL GUIDELINES DIAGNOSIS AND MANAGEMENT](https://reader031.vdocuments.mx/reader031/viewer/2022012915/61c641d59afa2677e5722175/html5/thumbnails/9.jpg)
9
![Page 10: LAST CLINICAL GUIDELINES DIAGNOSIS AND MANAGEMENT](https://reader031.vdocuments.mx/reader031/viewer/2022012915/61c641d59afa2677e5722175/html5/thumbnails/10.jpg)
10
![Page 11: LAST CLINICAL GUIDELINES DIAGNOSIS AND MANAGEMENT](https://reader031.vdocuments.mx/reader031/viewer/2022012915/61c641d59afa2677e5722175/html5/thumbnails/11.jpg)
11
![Page 12: LAST CLINICAL GUIDELINES DIAGNOSIS AND MANAGEMENT](https://reader031.vdocuments.mx/reader031/viewer/2022012915/61c641d59afa2677e5722175/html5/thumbnails/12.jpg)
12
![Page 13: LAST CLINICAL GUIDELINES DIAGNOSIS AND MANAGEMENT](https://reader031.vdocuments.mx/reader031/viewer/2022012915/61c641d59afa2677e5722175/html5/thumbnails/13.jpg)
13
![Page 14: LAST CLINICAL GUIDELINES DIAGNOSIS AND MANAGEMENT](https://reader031.vdocuments.mx/reader031/viewer/2022012915/61c641d59afa2677e5722175/html5/thumbnails/14.jpg)
14
![Page 15: LAST CLINICAL GUIDELINES DIAGNOSIS AND MANAGEMENT](https://reader031.vdocuments.mx/reader031/viewer/2022012915/61c641d59afa2677e5722175/html5/thumbnails/15.jpg)
15
![Page 16: LAST CLINICAL GUIDELINES DIAGNOSIS AND MANAGEMENT](https://reader031.vdocuments.mx/reader031/viewer/2022012915/61c641d59afa2677e5722175/html5/thumbnails/16.jpg)
16
Prevention and maintenance therapy:
I. Smoking cessation:
![Page 17: LAST CLINICAL GUIDELINES DIAGNOSIS AND MANAGEMENT](https://reader031.vdocuments.mx/reader031/viewer/2022012915/61c641d59afa2677e5722175/html5/thumbnails/17.jpg)
17
Prevention and maintenance therapy:
II. Vaccination for stable COPD:
![Page 18: LAST CLINICAL GUIDELINES DIAGNOSIS AND MANAGEMENT](https://reader031.vdocuments.mx/reader031/viewer/2022012915/61c641d59afa2677e5722175/html5/thumbnails/18.jpg)
18
Prevention and maintenance therapy:
III. Medical treatments:
![Page 19: LAST CLINICAL GUIDELINES DIAGNOSIS AND MANAGEMENT](https://reader031.vdocuments.mx/reader031/viewer/2022012915/61c641d59afa2677e5722175/html5/thumbnails/19.jpg)
19
![Page 20: LAST CLINICAL GUIDELINES DIAGNOSIS AND MANAGEMENT](https://reader031.vdocuments.mx/reader031/viewer/2022012915/61c641d59afa2677e5722175/html5/thumbnails/20.jpg)
20
![Page 21: LAST CLINICAL GUIDELINES DIAGNOSIS AND MANAGEMENT](https://reader031.vdocuments.mx/reader031/viewer/2022012915/61c641d59afa2677e5722175/html5/thumbnails/21.jpg)
![Page 22: LAST CLINICAL GUIDELINES DIAGNOSIS AND MANAGEMENT](https://reader031.vdocuments.mx/reader031/viewer/2022012915/61c641d59afa2677e5722175/html5/thumbnails/22.jpg)
22
Prevention and maintenance therapy:
IV. Oxygen therapy and ventilation support:
![Page 23: LAST CLINICAL GUIDELINES DIAGNOSIS AND MANAGEMENT](https://reader031.vdocuments.mx/reader031/viewer/2022012915/61c641d59afa2677e5722175/html5/thumbnails/23.jpg)
23
Prevention and maintenance therapy:
V. Interventional therapy:
![Page 24: LAST CLINICAL GUIDELINES DIAGNOSIS AND MANAGEMENT](https://reader031.vdocuments.mx/reader031/viewer/2022012915/61c641d59afa2677e5722175/html5/thumbnails/24.jpg)
24
![Page 25: LAST CLINICAL GUIDELINES DIAGNOSIS AND MANAGEMENT](https://reader031.vdocuments.mx/reader031/viewer/2022012915/61c641d59afa2677e5722175/html5/thumbnails/25.jpg)
25
![Page 26: LAST CLINICAL GUIDELINES DIAGNOSIS AND MANAGEMENT](https://reader031.vdocuments.mx/reader031/viewer/2022012915/61c641d59afa2677e5722175/html5/thumbnails/26.jpg)
26
![Page 27: LAST CLINICAL GUIDELINES DIAGNOSIS AND MANAGEMENT](https://reader031.vdocuments.mx/reader031/viewer/2022012915/61c641d59afa2677e5722175/html5/thumbnails/27.jpg)
27
![Page 28: LAST CLINICAL GUIDELINES DIAGNOSIS AND MANAGEMENT](https://reader031.vdocuments.mx/reader031/viewer/2022012915/61c641d59afa2677e5722175/html5/thumbnails/28.jpg)
28
![Page 29: LAST CLINICAL GUIDELINES DIAGNOSIS AND MANAGEMENT](https://reader031.vdocuments.mx/reader031/viewer/2022012915/61c641d59afa2677e5722175/html5/thumbnails/29.jpg)
29
![Page 30: LAST CLINICAL GUIDELINES DIAGNOSIS AND MANAGEMENT](https://reader031.vdocuments.mx/reader031/viewer/2022012915/61c641d59afa2677e5722175/html5/thumbnails/30.jpg)
30
![Page 31: LAST CLINICAL GUIDELINES DIAGNOSIS AND MANAGEMENT](https://reader031.vdocuments.mx/reader031/viewer/2022012915/61c641d59afa2677e5722175/html5/thumbnails/31.jpg)
31
![Page 32: LAST CLINICAL GUIDELINES DIAGNOSIS AND MANAGEMENT](https://reader031.vdocuments.mx/reader031/viewer/2022012915/61c641d59afa2677e5722175/html5/thumbnails/32.jpg)
33
![Page 33: LAST CLINICAL GUIDELINES DIAGNOSIS AND MANAGEMENT](https://reader031.vdocuments.mx/reader031/viewer/2022012915/61c641d59afa2677e5722175/html5/thumbnails/33.jpg)
34
![Page 34: LAST CLINICAL GUIDELINES DIAGNOSIS AND MANAGEMENT](https://reader031.vdocuments.mx/reader031/viewer/2022012915/61c641d59afa2677e5722175/html5/thumbnails/34.jpg)
35
![Page 35: LAST CLINICAL GUIDELINES DIAGNOSIS AND MANAGEMENT](https://reader031.vdocuments.mx/reader031/viewer/2022012915/61c641d59afa2677e5722175/html5/thumbnails/35.jpg)
36
![Page 36: LAST CLINICAL GUIDELINES DIAGNOSIS AND MANAGEMENT](https://reader031.vdocuments.mx/reader031/viewer/2022012915/61c641d59afa2677e5722175/html5/thumbnails/36.jpg)
37
![Page 37: LAST CLINICAL GUIDELINES DIAGNOSIS AND MANAGEMENT](https://reader031.vdocuments.mx/reader031/viewer/2022012915/61c641d59afa2677e5722175/html5/thumbnails/37.jpg)
38
![Page 38: LAST CLINICAL GUIDELINES DIAGNOSIS AND MANAGEMENT](https://reader031.vdocuments.mx/reader031/viewer/2022012915/61c641d59afa2677e5722175/html5/thumbnails/38.jpg)
39
COPD and comorbidities
![Page 39: LAST CLINICAL GUIDELINES DIAGNOSIS AND MANAGEMENT](https://reader031.vdocuments.mx/reader031/viewer/2022012915/61c641d59afa2677e5722175/html5/thumbnails/39.jpg)